Joe Brady

Corporate Development & Innovation

Greater Boston

About

Passionate scientist-entrepreneur dedicated to creating and advancing first-in-class bioplatform companies for a future of better health. Operating at the interface of science and business to drive an integrated value creation strategy for the platform, portfolio, and business.

Experience

  • Ampersand Biomedicines (Boston, Massachusetts, United States)
    • Senior Director, Corporate Development and Platform Innovation
      Mar 2025 - Present · 1 yr 4 mos

    • Director, Corporate Development and Platform Innovation
      Jan 2024 - Mar 2025 · 1 yr 3 mos

  • Flagship Pioneering (Cambridge, Massachusetts, United States)
    • Senior Associate
      Sep 2022 - Jan 2024 · 1 yr 5 mos

      Co-founded or advanced 5 portfolio companies from origination to growth stage, culminating in day-to-day operational leadership of a 10-person company.

    • Associate
      Oct 2020 - Aug 2022 · 1 yr 11 mos

    • VentureLabs Fellow
      Jun 2020 - Sep 2020 · 4 mos

  • PhD Candidate, Love Lab, David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology
    Sep 2015 - Apr 2020 · 4 yrs 8 mos

    Collaborated with DARPA, Gates Foundation, and a consortium of large pharma to develop an alternative yeast host for the production of therapeutic mAbs, proteins and vaccines; leveraged multi-omics techniques and built synthetic biology tools to deliver program objectives. Supported go-to-market strategy for a lab-grown startup, including at pitch competitions and incubator programs sponsored by MIT Sloan and MIT's The Engine.

  • Technician, Process Science at The Janssen Pharmaceutical Companies of Johnson & Johnson
    2015 - 2015 · Less than a year

    Supported the development and validation of an implanted medical device containing stem cells to regulate blood glucose levels for the treatment of diabetes. Collaborated with internal BetaLogics project team.

  • Research Associate (Contract), Cell Line Optimization at GSK
    2014 - 2014 · Less than a year

    Engineered and developed bacterial and mammalian master cell lines/banks to support preclinical development/CMC. Also supported the development of a half-life extension platform for recombinant protein and peptide therapeutics.